Strong ANXA1 expression has been reported in various malignancies, such as melanoma [62], glioma [63], breast cancer [64], lung cancer [65], hepatocellular carcinoma [66], and CRC [67,68], including LARC [27], being mostly associated with a poor prognosis along with a reduced overall survival (OS) and disease-free survival (DFS) [65,66]. Here, ANXA1 is linked to central nervous system cancer.